TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq review
PUBT · 2d ago
Share
Listen to the news
- TransCode Therapeutics adjourned its 2026 annual shareholder meeting to July 20 from July 2.
- Delay tied to Nasdaq Listing Rule 5110(a) review required before a vote on converting Series A and Series B non-voting preferred stock.
- Preliminary vote tallies showed all meeting proposals had enough shareholder support for passage.
- Nasdaq has not completed its review of the company’s initial listing application, creating timing uncertainty.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080311), on July 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved